Imunon counsel sells 2,449 shares at $1.63 avg

Imunon, Inc. executive Susan Eylward, General Counsel and Corporate Secretary, reported two transactions in Imunon common stock.

Rhea-AI Filing Summary

Imunon, Inc. executive Susan Eylward, General Counsel and Corporate Secretary, reported two transactions in Imunon common stock. On August 14, 2026, she acquired 2,449 shares as stock granted in lieu of cash for a portion of base salary at an indicated value of $1.65 per share. On August 17, 2026, she sold 2,449 shares in an open-market or private transaction at a weighted average price of $1.6303 per share, with individual sale prices ranging from $1.61 to $1.655 per share. Post-transaction share holdings are not stated in this report.

Insider Trade Summary

Net Seller: 2,449 shares

Net Sell 2 txns

Insider Eylward Susan

Role General Counsel and Corp Sec

Sold 2,449 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock F2	2,449	$1.6303	$4K
Grant/Award	Common Stock F1	2,449	$1.65	$4K

Holdings After Transaction: Common Stock — 2,896 shares (Direct)

Footnotes (2)

1. F1. Stock granted in lieu of cash for portion of base salary
2. F2. Reflects a weighted average sale price of $1.6303 per share, at prices ranging from $1.61 to $1.655 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.

Key Figures

Shares granted: 2,449 shares Grant value per share: $1.65 per share Shares sold: 2,449 shares +3 more

6 metrics

Shares granted 2,449 shares Common stock granted on August 14, 2026 in lieu of cash salary

Grant value per share $1.65 per share Indicated value for stock granted in lieu of cash salary

Shares sold 2,449 shares Common stock sale on August 17, 2026

Weighted average sale price $1.6303 per share Average price for shares sold on August 17, 2026

Sale price range low $1.61 per share Lowest price in the sale range on August 17, 2026

Sale price range high $1.655 per share Highest price in the sale range on August 17, 2026

Key Terms

Form 4, weighted average sale price, in lieu of cash

3 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

weighted average sale price financial

"Reflects a weighted average sale price of $1.6303 per share"

in lieu of cash financial

"Stock granted in lieu of cash for portion of base salary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did IMNN’s Susan Eylward report on this Form 4?

Susan Eylward reported two transactions: a grant of 2,449 IMNN shares on August 14, 2026, and a sale of 2,449 shares on August 17, 2026. Both transactions involved Imunon, Inc. common stock and were reported as direct ownership.

How many Imunon (IMNN) shares did Susan Eylward sell and at what price?

Susan Eylward sold 2,449 IMNN shares on August 17, 2026, at a weighted average price of $1.6303 per share. The filing states that individual sale prices ranged from $1.61 to $1.655 per share in open-market or private transactions.

What stock award did Susan Eylward of IMNN receive according to this Form 4?

On August 14, 2026, Susan Eylward received an award of 2,449 IMNN common shares. A footnote explains the stock was granted in lieu of cash for a portion of her base salary, with an indicated value of $1.65 per share for this grant.

Were Susan Eylward’s IMNN transactions part of a derivative or option exercise?

No, both reported transactions involve non-derivative IMNN common stock. One entry is a grant or award acquisition of 2,449 shares, and the other is a sale of 2,449 shares. The filing’s derivative summary shows no derivative transactions reported in this instance.

Does the Form 4 state Susan Eylward’s IMNN share balance after these trades?

The Form 4 does not state Susan Eylward’s total IMNN holdings after these transactions. For both the grant of 2,449 shares and the sale of 2,449 shares, the field for shares owned following the transaction is left blank in the reported data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 04:18 PM Accepted by SEC EDGAR 08/17/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eylward Susan

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Corp Sec

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		A		2,449(1)	A	$1.65	5,345	D
Common Stock	08/17/2026		S		2,449	D	$1.6303(2)	2,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of base salary

2. Reflects a weighted average sale price of $1.6303 per share, at prices ranging from $1.61 to $1.655 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.

	/s/ Susan Eylward	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)